SEC Form 4 · accession 0001140361-15-012986
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sunil Patel
Officer — See Remarks
Period of report
Mar 19, 2015
Accepted (ET)
Mar 23, 2015 · 8:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 19, 2015 | M | 3,335 | $3.42 | A | 23,335 | D | |
| Common StockF2,F1 | Mar 19, 2015 | S | 3,335 | $27.3422 | D | 20,000 | D | |
| Common StockF1 | Mar 20, 2015 | M | 14,665 | $3.42 | A | 34,665 | D | |
| Common StockF3,F1 | Mar 20, 2015 | S | 14,665 | $27.8584 | D | 20,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $3.42 | Mar 19, 2015 | M | 3,335 | D | — | Jul 30, 2019 | Common Stock | 3,335 | 116,260 | D |
| Stock Option (Right to Buy)F4 | $3.42 | Mar 20, 2015 | M | 14,665 | D | — | Jul 30, 2019 | Common Stock | 14,665 | 101,595 | D |
Explanation of responses
- F1Includes 20,000 Restricted Stock Units.
- F2Transaction executed in multiple trades at prices ranging from $27.34 to $27.3701 per share, inclusive. The price reported in column 4 above reflects the weighted average sale price per share. The Reporting Person hereby undertakes to provide the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3Transaction executed in multiple trades at prices ranging from $27.66 to $27.99 per share, inclusive. The price reported in column 4 above reflects the weighted average sale price per share. The Reporting Person hereby undertakes to provide the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4The option is fully vested and exercisable.
Remarks
Chief Financial Officer and Senior Vice President, Corporate Development and Finance